Medtide (HKG:3880) completed the conversion of 68.2 million unlisted shares into Hong Kong-listed shares on Monday, according to a same-day Hong Kong bourse filing.
The listing of the peptide-focused CRDMO's converted shares on the Hong Kong stock exchange will begin at 9:00 am on March 10.